Seoul, Korea
Galux was established in 2020 with the incorporation of molecular design technology that has been honed over a period of 15 years at Seoul National University. This technology leverages the integration of AI, physics, and chemistry to produce exceptional results, as evidenced by its performance in the CASP and CAPRI competitions. Built on a foundation of advanced research and development capabilities, Galux is currently developing a drug design platform that incorporates protein structure prediction, protein-protein interaction prediction, and protein-ligand interaction prediction technologies. The company is also focused on identifying and developing novel therapeutics for incurable and rare diseases through its AI-based drug design platform
No key contacts have been added to this profile yet.
No reviews have been added to this profile yet.
This is the company profile page for Galux on the Pharmaceutical Services Directory. Companies listed on the directory can update their business information free of charge. If this is your company and you'd like to claim this profile, please Contact Us.
